NCT05954780View on ClinicalTrials.gov

Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Selinexor

Selinexor/bortezomib/dexamethasone according to Nexpovio® SmPC

Trial Locations (2)

1090

NOT_YET_RECRUITING

Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Vienna

88212

RECRUITING

Gemeinschaftspraxis für Hämatologie und Onkologie GbR, Ravensburg

All Listed Sponsors
collaborator

Menarini Stemline

UNKNOWN

collaborator

Climedo Health GmbH

UNKNOWN

lead

iOMEDICO AG

INDUSTRY

NCT05954780 - Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter